Mallinckrodt Pharmaceuticals is merging with Endo International in a $6.7 billion deal, creating a combined company focused on specialty pharmaceuticals.

Overview of the Deal

The acquisition of Endo International by Mallinckrodt Pharmaceuticals represents a significant merger in the pharmaceutical industry, aimed at creating a combined company with an implied enterprise value of $6.7 billion. The agreement, announced on March 13, 2025, entails a stock and cash transaction where Endo shareholders will receive $80 million in cash, subject to adjustments, and will hold 49.9% of the new entity, while Mallinckrodt shareholders will retain a controlling 50.1% stake. The merger combines the strengths of both companies, which have recently reorganized following extensive opioid litigation.

This transaction includes a refinancing element and will be financed through cash reserves and a committed $900 million facility from Goldman Sachs. Upon completion, the merged entity will be listed on the New York Stock Exchange (NYSE) and will operate under the Mallinckrodt brand, with Endo becoming a wholly-owned subsidiary.

Information on the Target: Endo International

Founded in 1920 and headquartered in Pennsylvania, USA, Endo International has established itself as a multinational healthcare and pharmaceutical leader, focusing on various segments including Branded Pharmaceuticals, Sterile Injectables, Ge